These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 28500695)

  • 1. Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort.
    Lammi MR; Saketkoo LA; Gordon JK; Lauto P; Fagan K; Steen VD;
    Respirology; 2017 Oct; 22(7):1386-1392. PubMed ID: 28500695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.
    Valerio CJ; Schreiber BE; Handler CE; Denton CP; Coghlan JG
    Arthritis Rheum; 2013 Apr; 65(4):1074-84. PubMed ID: 23280155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
    Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
    Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).
    Kolstad KD; Li S; Steen V; Chung L;
    Chest; 2018 Oct; 154(4):862-871. PubMed ID: 29777655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular end-diastolic pressure.
    Dickinson MG; Lam CS; Rienstra M; Vonck TE; Hummel YM; Voors AA; Hoendermis ES
    Eur J Heart Fail; 2017 Nov; 19(11):1483-1490. PubMed ID: 28948687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
    Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
    Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry.
    Hsu VM; Chung L; Hummers LK; Shah A; Simms R; Bolster M; Hant FN; Silver RM; Fischer A; Hinchcliff ME; Varga J; Goldberg AZ; Derk CT; Schiopu E; Khanna D; Shapiro LS; Domsic RT; Medsger T; Mayes MD; Furst D; Csuka ME; Molitor JA; Saketkoo LA; Salazar CR; Steen VD
    J Rheumatol; 2019 Feb; 46(2):176-183. PubMed ID: 30275260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease.
    Tampakakis E; Leary PJ; Selby VN; De Marco T; Cappola TP; Felker GM; Russell SD; Kasper EK; Tedford RJ
    JACC Heart Fail; 2015 Jan; 3(1):9-16. PubMed ID: 25453535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension.
    Fox BD; Shimony A; Langleben D; Hirsch A; Rudski L; Schlesinger R; Eisenberg MJ; Joyal D; Hudson M; Boutet K; Serban A; Masetto A; Baron M
    Eur Respir J; 2013 Oct; 42(4):1083-91. PubMed ID: 23258775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.
    Hsu VM; Chung L; Hummers LK; Wigley F; Simms R; Bolster M; Silver R; Fischer A; Hinchcliff ME; Varga J; Goldberg AZ; Derk CT; Schiopu E; Khanna D; Shapiro LS; Domsic RT; Medsger T; Mayes MD; Furst D; Csuka ME; Molitor JA; Alkassab F; Steen VD
    Semin Arthritis Rheum; 2014 Aug; 44(1):55-62. PubMed ID: 24709277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.
    Lefèvre G; Dauchet L; Hachulla E; Montani D; Sobanski V; Lambert M; Hatron PY; Humbert M; Launay D
    Arthritis Rheum; 2013 Sep; 65(9):2412-23. PubMed ID: 23740572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component.
    Caravita S; Faini A; Carolino D'Araujo S; Dewachter C; Chomette L; Bondue A; Naeije R; Parati G; Vachiéry JL
    PLoS One; 2018; 13(6):e0199164. PubMed ID: 29920539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension.
    Lui JK; Sangani RA; Gillmeyer KR; Vakhshoorzadeh J; Trojanowski MA; Bujor AM; Gopal DM; Wiener RS; LaValley MP; Klings ES
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):651-656. PubMed ID: 36607535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants and prognostic implications of the negative diastolic pulmonary pressure gradient in patients with pulmonary hypertension due to left heart disease.
    Nagy AI; Venkateshvaran A; Merkely B; Lund LH; Manouras A
    Eur J Heart Fail; 2017 Jan; 19(1):88-97. PubMed ID: 27748008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Diagnostic Challenge of Group 2 Pulmonary Hypertension.
    Naeije R; D'Alto M
    Prog Cardiovasc Dis; 2016; 59(1):22-9. PubMed ID: 27195751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry.
    Hinchcliff M; Khanna S; Hsu VM; Lee J; Almagor O; Chang RW; Steen V; Chung L;
    Semin Arthritis Rheum; 2015 Dec; 45(3):309-14. PubMed ID: 26210782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients.
    Hager WD; Collins I; Tate JP; Azrin M; Foley R; Lakshminarayanan S; Rothfield NF
    Clin Respir J; 2013 Jul; 7(3):227-36. PubMed ID: 22789029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension.
    Tedford RJ; Beaty CA; Mathai SC; Kolb TM; Damico R; Hassoun PM; Leary PJ; Kass DA; Shah AS
    J Heart Lung Transplant; 2014 Mar; 33(3):289-97. PubMed ID: 24462554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.
    Hinchcliff M; Fischer A; Schiopu E; Steen VD;
    J Rheumatol; 2011 Oct; 38(10):2172-9. PubMed ID: 21844142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry.
    Chung L; Farber HW; Benza R; Miller DP; Parsons L; Hassoun PM; McGoon M; Nicolls MR; Zamanian RT
    Chest; 2014 Dec; 146(6):1494-1504. PubMed ID: 24992469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.